14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...
21:39 , Nov 30, 2018 |  BC Week In Review  |  Company News

Boston Scientific to acquire London-based BTG

Boston Scientific Corp. (NYSE:BSX) will acquire BTG plc (LSE:BTG) for about £3.3 billion ($4.2 million) in cash. BTG shareholders will receive 840p per share. The acquisition is expected to close 1H19. BTG develops products used...
19:56 , Nov 2, 2018 |  BC Week In Review  |  Company News

J&J appeals district court decision invalidating Zytiga patent

Johnson & Johnson (NYSE:JNJ) on Oct. 31 filed to appeal a district court decision that will permit generic versions of prostate cancer drug Zytiga abiraterone acetate to launch after Oct. 31, according to company spokesperson...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro , cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based...
18:12 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibition or inverse agonism of NR5A2 could help treat prostate cancer. In a human prostate cancer line expressing high levels of NR5A2 cultured in androgen-deprived bovine serum, siRNA...
19:13 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; colorectal cancer Mouse studies suggest combining inhibitors of TGFβ signaling with anti-PD-L1 therapies could help treat breast and colorectal cancers. In a mouse model of breast cancer in which T cells cannot...
19:39 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA expands label for Zytiga

Johnson & Johnson (NYSE:JNJ) said FDA approved a new indication for Zytiga abiraterone acetate (CB7630) in combination with prednisone to treat metastatic high-risk castration-sensitive prostate cancer (CSPC). The approval is based on data from a...